Amgen-Applied Molecular Genetics Co   Term Paper ID:27976 Click to get this paper

Essay Subject: (1991) Amgem, a bio-medical company, is examined in terms of: history/background; innovative capabilities; resource availability; competitor strategies; technological development; structural & cultural context; new product development; & recommendations.... More...

8 Pages / 1800 Words 8 sources, 6 Citations, APA Format $32.00 Return to List of Papers

Paper Abstract: (1991) Amgem, a bio-medical company, is examined in terms of: history/background; innovative capabilities; resource availability; competitor strategies; technological development; structural & cultural context; new product development; & recommendations. Paper Introduction: BACKGROUND HISTORY OF THE COMPANY Amgen was formed as Applied Molecular Genetics in 1980. A group of scientists and venture capitalists banded together with the common goal of developing human and animal health care products based on molecular biological technology. The company is headquartered in Los Angeles and is today the world's number one independent company. Sales have grown 103 percent annually over the past four years and might pass $1 billion in 1992. The company's success rests almost entirely on two products developed using recombinant DNA technology, also known as "gene splicing." George Rathmann was a vice president at Abbott Laboratories and was recruited as the company's first CEO and first employee. He decided to direct the company toward developing a few potentially Text of the Paper: The entire text of the paper is shown below. However, the text is somewhat scrambled. We want to give you as much information as we possibly can about our papers and essays, but we cannot give them away for free. In the text below you will find that while disordered, many of the phrases are essentially intact. From this text you will be able to get a solid sense of the writing style, the concepts addressed, and the sources used in the research paper. molecularbiological technology The company is headquartered in almost entirely on two productsdeveloped company toward developing a few potentially proximity to suchimportant research centers as protein erythropoietin EPO which stimulates red bloodcell in for the development and marketing of EPO other marketing ventures after this allocation of sales proceeds Amgen created a tiewith million inRegeneron Pharmaceuticals a New York company patients Alsoin the federal judiciary denied permission to in favor of Amgen and Chugaiwas ordered to renounce its most of its history one ofdozens approval of Epogen It was then faced with the drug to the market The company executivesadmitted that they capital The company has been searching for companystarted trials of G-CSF for burn cases theyhave contracted infections such as pneumonia Aside speed the healing of bedsores and wounds as yet Amgen recently startedtrials on a stem-cell In order to have more products to sell Amgen cells Thiswould have application for Amgen introduced its two major products with making the sort of exaggerated claims that was only in the early s after the same or products Once it was as improved drug-delivery systems forchemotherapy but the only company to be trulysuccessful By Amgen was growing rapidly expanding its facilities the manufacture and marketing of Europe Erdman pp INNOVATIVE CAPABILITIES terms of the delivery or sale for products that have already been approved for sale not providethe needed financing for the sort of product this is not certain One problem with this type it may never occur at all Companiesare It has made the necessaryconnections to other companies for added of needed finances and is tryingto overcome companies are doing andwhich companies are researching in understandingthe way the business is evolving technologyoutstrips what is being done today This is rapidly Amgen isin a position to understand this the mostobvious area of uncertainty where the greatest trying to acquire the funds through entrepreneurialinitiatives by its lack of R D financing company is dedicated to developing new productsbut is limited for the end of this decade or whether it will to diversify to maintain its lead and to more such possibilities Joint ventures have also been company orone that takes a broader approach based until new products can be broughtto keep that family feeling April Fortune pp Flynn J pp Hoover G Campbell A Spain R J eds and venture capitalists banded together with the common goal ofdeveloping percent annually over the past four years and might pass and wasrecruited as the company's first CEO support Amgen's initial efforts The headquarterswere placed until It was then that company market Based on this important G-CSF another human protein usedto stimulate the body's immune system subsidiaryof Johnson Johnson This would later lead to the brand name ofEGO for the treatment company permission to market Neupogen on the product In a license rights to its own G-CSF patents Hoover Campbell Genex However by Amgen had emerged asthe world's premier independent a large enoughreserve base to fund the million and up into the late s The two products thatwere effective would be the sameas developing a new product infection Amgen was also to explore way of new products for the lasthalf of the has also beenworking in this to Neupogen except thatit would stimulate toinvest million in Regeneron as noted to fund research and a decade away however so ways have to thepatent dispute with Genetics Institute Inc companies are working on the sameproducts S Patent Office had been deluged withsome applications that between Amgen and Genentech It is expected that biotech companies were ready to its pioneering diagnostic test for hepatitis Cvirus the introductionof Neupogen in Canada and Australia and a itself as a biotech firm industry requirements andpractices but the company is attempting to and approvalprocess The firm's current late s The companyhas a strategy can occur in a shortperiod of time same thing The firm needs financing product test it andgain approval Resource Availability The sufficient resourcesaside from the financial issue Competitor research first and to gain thepatent for a given product this is such a new area offocus that will prepare Technological Development As noted to make breakthroughs and to develop new Cultural Context Amgen is dedicated to finding the and seeking funding through stock offerings Entrepreneurial Initiatives Amgen is DEVELOPMENT The issue of new product development has the issue facing the company not be until the next decade before to a degree by buying products from an earlier attempt there are dangers inthis approach the image of Amgen as a niche own tough act March Business Week pp Blood Money Fighting over a splice of life U S News BACKGROUND HISTORY OF THE COMPANY Amgen was formed as Los Angeles and istoday the world's using recombinant DNA technology also known as gene splicing profitable productsrather than conducting general the California Institute of Technology UCLA and UC Santa Barbara production in the body Amgen made its first The two companies also collaborated first on the basis of anagreement for Roche Holdings in The company was greatly benefited in involved in the developmentof neurotrophic nerve cell growth Genetics Institute tomarket its version of EGO U S patents for its version of of biotechnology startups in the shadow of problem of sustainingits growth One did not have enough promising new products ready new uses for theseproducts If Amgen in which patients have a normallevel from such hoped-for developments with but as yet there areno factor protein that treats bone marrow damaged byradiation or has been licensingproducts from smaller treatment of Alzheimer's or Parkinson'sdiseases Products from little fanfare for anumber of reasons One problem facing the had gotten Genentech intotrouble Hamilton Brown pp This illustrates when the Supreme Court decided that companies had established thatpatents could be won and or will attack complex diseases such as as yet has been Amgen Chiron inThousand Oaks and increasing its workforce by percent each year Amgen has been innovative in developing of the product is curtailed bythe requirements though such newuses as well would have development that is necessaryfor the of business is that no schedule can be further faced with stiff competition support It is faced with this by developing new uses for existing products even as the same specific areas There and the sorts of problems to beencountered in an area of uncertainty whichevery company will fact and to benefit from changes as theyare made change is possible in waysthat cannot a variety ofmeans joining with at this time though the company as noted by financial considerations time considerations andtechnological considerations New product not be until thenext decade before they reach the continue toraise the money needed to support future research and offered as a strategy but on its technological capabilitiesand the products it feels it can market REFERENCESAmgen is hot and bothered January Business Week pp The hormone that's making Amgen grow March Business Hoover's Handbook of American Business New York Reference Press human and animal health care products based on billion in The company's success rests and first employee He decided todirect the at Thousand Oaks California because of its scientist Fu-Kuen Lincloned the human discovery Amgen formed a joint venture withKirin Brewery of Japan to combat bacterial infection Therewere disputes between the twocompanies concerning the of anemia In Amgen invested thebrand name of its G-CSF for the treatment of chemotherapy patent dispute with Genetic Institute'spartner Chugai Pharmaceutical was resolved Spain p Amgen remained an anonymous company for biotech company Amgen grew rapidly withthe needed for research anddevelopment to bring a new for the company however might also provide some of thisneeded as far as sales are concerned The whether Neupogen could help patients after s The company has been working on tissue-growth factorsthat could area also with no results production of a broader array of blood cells developmenton two nerve-growth factors to influence the growth of brain be found in the meantime to finance developmentwork Armstrong pp The company also wanted toavoid and this is common in biotechnology It The technology is very new and companies havebeen that companieshereafter will focus on niches such blossomin the early s with high profits and this came after eight years of losses Giltenan pp product development team of overseeing in a completely new field Innovation in be innovative by finding newuses business and corporate strategies do that might provide such funding but or over many years or for innovative capabilities It hassufficient personnel and sufficient expertise company has a shortage in terms Strategies The company is fully aware of what other Amgen is also fully capable of it could be changed radically within a few years if this is the area that may change the most technologies throughresearch and development while Amgen does not This remains means to develop new products andthe business unit has been restricted in its ability to deal with been addressed at lengthabove but essentially the is whether any new products can bedeveloped the company has anythingnew to offer RECOMMENDATIONS Amgen may need othercompanies for distribution Amgen should explore Amgen should decide whether it will be a niche company thoughthis image may be unavoidable for a time April The Economist pp Erdman A How to World Report p Gilteman E Bioprofits January Forbes Applied Molecular Genetics in A group ofscientists number one independent company Sales have grown George Rathmann was a vice president at Abbott Laboratories research The company was then able toraise million to Still the company operated dangerously close tobankruptcy public stock offeringthat same year with million shares on the on the development of recombinant humangranulocyte colony-stimulating factor marketing with Ortho Pharmaceutical Corporation a when the FDA granted Amgen a license to produce Epogen products In the FDA gave the which effectively gave Amgen a monopoly a U S monopoly G-CSF andassign Amgen its U S the industry's Big Four Genentech Biogen Cetus and concern was that the company did not have to goto propel the company ahead could give the drugs new uses that of neutrophils but are in danger of getting bacterial existing products executives could point to little in the dramatic gains in clinical trials Chiron Corporation chemotherapy This would be similar biotech companies In the company agreed these collaborations are at least company at the time was some of thedangers encountered when different the right to patentmicroorganisms and by the U enforced litigation between companies ensued such as Alzheimer's andParkinson's Gabor Dworkin p In Forbes predicted Corp has also been prosperingonce it received approval of Thecompany has a person task force that recently organized its two products and in theway it has created of FDA approval and similar to pass through the same review company to expand even further into the devisedfor discovering a new product Such a discovery from a number of other companiesall trying to do the thereality that it takes time to develop this sort of itcontinues trying to develop new products It has isconsiderable competition to complete the the future At the same time try to foresee and for which they though some of the larger companies have the financial supportneeded be foreseen clearly Structural and other companies for joint ventures developing new usesfor existing products is trying to overcome this limitation NEW PRODUCT development is moving forward but market At the present time it seemsthat it will development efforts The company has been doing this as can be seenfrom the lawsuits generated by develop Finding new uses for existingproducts tends to reinforce Armstrong L Can amgen follow its Week pp Gabor A Dworkin P November Inc molecularbiological technology The company is headquartered in almost entirely on two productsdeveloped company toward developing a few potentially proximity to suchimportant research centers as protein erythropoietin EPO which stimulates red bloodcell in for the development and marketing of EPO other marketing ventures after this allocation of sales proceeds Amgen created a tiewith million inRegeneron Pharmaceuticals a New York company patients Alsoin the federal judiciary denied permission to in favor of Amgen and Chugaiwas ordered to renounce its most of its history one ofdozens approval of Epogen It was then faced with the drug to the market The company executivesadmitted that they capital The company has been searching for companystarted trials of G-CSF for burn cases theyhave contracted infections such as pneumonia Aside speed the healing of bedsores and wounds as yet Amgen recently startedtrials on a stem-cell In order to have more products to sell Amgen cells Thiswould have application for Amgen introduced its two major products with making the sort of exaggerated claims that was only in the early s after the same or products Once it was as improved drug-delivery systems forchemotherapy but the only company to be trulysuccessful By Amgen was growing rapidly expanding its facilities the manufacture and marketing of Europe Erdman pp INNOVATIVE CAPABILITIES terms of the delivery or sale for products that have already been approved for sale not providethe needed financing for the sort of product this is not certain One problem with this type it may never occur at all Companiesare It has made the necessaryconnections to other companies for added of needed finances and is tryingto overcome companies are doing andwhich companies are researching in understandingthe way the business is evolving technologyoutstrips what is being done today This is rapidly Amgen isin a position to understand this the mostobvious area of uncertainty where the greatest trying to acquire the funds through entrepreneurialinitiatives by its lack of R D financing company is dedicated to developing new productsbut is limited for the end of this decade or whether it will to diversify to maintain its lead and to more such possibilities Joint ventures have also been company orone that takes a broader approach based until new products can be broughtto keep that family feeling April Fortune pp Flynn J pp Hoover G Campbell A Spain R J eds and venture capitalists banded together with the common goal ofdeveloping percent annually over the past four years and might pass and wasrecruited as the company's first CEO support Amgen's initial efforts The headquarterswere placed until It was then that company market Based on this important G-CSF another human protein usedto stimulate the body's immune system subsidiaryof Johnson Johnson This would later lead to the brand name ofEGO for the treatment company permission to market Neupogen on the product In a license rights to its own G-CSF patents Hoover Campbell Genex However by Amgen had emerged asthe world's premier independent a large enoughreserve base to fund the million and up into the late s The two products thatwere effective would be the sameas developing a new product infection Amgen was also to explore way of new products for the lasthalf of the has also beenworking in this to Neupogen except thatit would stimulate toinvest million in Regeneron as noted to fund research and a decade away however so ways have to thepatent dispute with Genetics Institute Inc companies are working on the sameproducts S Patent Office had been deluged withsome applications that between Amgen and Genentech It is expected that biotech companies were ready to its pioneering diagnostic test for hepatitis Cvirus the introductionof Neupogen in Canada and Australia and a itself as a biotech firm industry requirements andpractices but the company is attempting to and approvalprocess The firm's current late s The companyhas a strategy can occur in a shortperiod of time same thing The firm needs financing product test it andgain approval Resource Availability The sufficient resourcesaside from the financial issue Competitor research first and to gain thepatent for a given product this is such a new area offocus that will prepare Technological Development As noted to make breakthroughs and to develop new Cultural Context Amgen is dedicated to finding the and seeking funding through stock offerings Entrepreneurial Initiatives Amgen is DEVELOPMENT The issue of new product development has the issue facing the company not be until the next decade before to a degree by buying products from an earlier attempt there are dangers inthis approach the image of Amgen as a niche own tough act March Business Week pp Blood Money Fighting over a splice of life U S News If this paper is not what you are looking for, you can search again: Search for: or Click here to request an essay written just for you.

Custom Papers:   Would you like our specialists to write an original, personalized term paper, essay, or research paper JUST for you?  No problem!  We will write a unique paper matching the EXACT instructions that you provide to us.  We can provide research material in MLA, APA, Chicago, Harvard, and Turabian styles.  No matter what type of paper you need for research, we can help immediately!  You—and ONLY you—will receive the one-of-a-kind paper that you order!  Depending on the level of difficulty and the number of pages you require, we can conduct the necessary research, write the paper from scratch, and email it to you in as little as 10 hours.  And, because we have such great confidence in our researching/writing expertise, we will re-write the paper for free if it does not match the instructions in your original order.  You are in good hands with Term-Papers-College.com!

  Home
  Samples


  Subjects A-Z
  Guarantee


  Search
  Search Questions


  Custom Research
  Custom Questions


  Privacy
  International